e-learning
resources
Breathe
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
Gabriella Long, Jasmine Wall
Source:
Breathe, 14 (4) 338; 10.1183/20734735.026318
Journal Issue:
December
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Gabriella Long, Jasmine Wall. Precision medicine in COPD: review of mepolizumab for eosinophilic COPD. Breathe, 14 (4) 338; 10.1183/20734735.026318
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Medication use in COPD: systematic review and meta-analysis
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007
Mepolizumab in COPD with eosinophilic bronchitis: A randomized clinical trial
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Bronchodilators delivered by nebuliser versus pMDI for exacerbations of COPD - A Cochrane review
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Eosinophilic airway inflammation as a complication of COPD, and the usefulness of ICS on these cases
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Outcomes of COPD exacerbations - a report from the ERS COPD audit in Austria
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013
Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017
Hospital adherence to GOLD guidelines for COPD exacerbation. Results of the European CODP audit
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013
Misdiagnosed COPD: systematic review and meta-analysis
Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care
Year: 2007
Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<%
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Compare clinical effectiveness of various types of bronchodilators in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Source: Eur Respir J 2007; 29: 906-913
Year: 2007
The best papers in the ERJ: chronic airways diseases, including asthma and COPD
Source: Virtual Congress 2020 – The European Respiratory Journal editor's view: our best papers of last year
Year: 2020
Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept